A practical reference on Synaptogenesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Titration: Metrohm offers different titration systems, including potentiometric, thermometric, and Karl Fischer titrators. The Omnis software provides a modular and scalable framework for titration workflows, including options for integrated sample handling and digital data management. Ion chromatography (IC): Metrohm provides instruments for determining anions, cations, and organic substances at trace and ultra-trace levels, used in industries such as pharmaceuticals, chemicals, and environmental analysis. Electrochemistry and Voltammetry: Metrohm supplies potentiostats, galvanostats, and accessories for electrochemical research and trace analysis of metals. Spectroscopy: The company's spectroscopy range includes instruments for near-infrared (NIR) and Raman spectroscopy, such as portable and laboratory Raman analyzers and NIR spectrometers. Process analytics: Metrohm offers modular systems for real-time online monitoring of industrial processes using titration, ion chromatography, and spectroscopy. Metrohm collaborates with external partners to develop fully automated laboratory robots for sample preparation and analysis. Metrohm also offers pH meters, conductivity meters, dosing systems, and software for data management and compliance.
In 1649, German scientist and inventor Otto von Guericke invented the spool vacuum air pump. Guericke's vacuum pump decreased any potential leaks between the piston and the cylinder by utilizing washers made from leather. In Britain, the first effective vacuum pump for scientific purposes was constructed in 1658 by English polymath Robert Hooke, on behalf of Anglo-Irish natural philosopher Robert Boyle. Boyle used the term "air pump" (among others) for his own vacuum pump as well as Guericke's, and they have often been referred to as such ever since. In 1705, English scientist Francis Hauksbee, developed a style of a double-barrelled air pump. Hauksbee's double-barrelled air pump was used primarily for scientific research, and had the ability to create a vacuum.
=== Medications === Oral medications like Glipizide that stimulate the pancreas, promoting insulin release (or in some cases, reduce glucose production), are less and less used in cats, and these drugs may be completely ineffective if the pancreas is not working. These drugs have also been shown in some studies to damage the pancreas further or to cause liver damage. Some owners are reluctant to switch from pills to insulin injections, but the fear is unjustified; the difference in cost and convenience is minor (most cats are easier to inject than to pill), and injections are more effective at treating the disease. Bexagliflozin (Bexacat) was approved for medical use in the United States in December 2022. It is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and Drug Administration (FDA) in any animal species. Velagliflozin (Senvelgo), another SGLT2 inhibitor, was approved for medical use in the United States in August 2023 by the FDA. SGLT2 inhibitors are not insulin, nor do they help a diabetic cat's cells use glucose for energy. SGLT2 inhibitors lowers blood glucose levels by excreting glucose through the kidneys. Both medications are prescription only and are given orally (by mouth) once daily. Cats that have been previously treated with long-term insulin therapy, are currently on long-term insulin therapy, or has other underlying health conditions should not take these medications.
Aldosterone is the main mineralocorticoid steroid hormone produced by the zona glomerulosa of the adrenal cortex in the adrenal gland. It is essential for sodium conservation in the kidney, salivary glands, sweat glands, and colon. It plays a central role in the homeostatic regulation of blood pressure, plasma sodium (Na+), and potassium (K+) levels. It does so primarily by acting on the mineralocorticoid receptors in the distal tubules and collecting ducts of the nephron. It influences the reabsorption of sodium and excretion of potassium (from and into the tubular fluids, respectively) of the kidney, thereby indirectly influencing water retention or loss, blood pressure, and blood volume. When dysregulated, aldosterone is pathogenic and contributes to the development and progression of cardiovascular and kidney disease. Aldosterone has exactly the opposite function of the atrial natriuretic hormone secreted by the heart. Aldosterone is part of the renin–angiotensin–aldosterone system. It has a plasma half-life of less than 20 minutes. Drugs that interfere with the secretion or action of aldosterone are in use as antihypertensives, like lisinopril, which lowers blood pressure by blocking the angiotensin-converting enzyme (ACE), leading to lower aldosterone secretion. The net effect of these drugs is to reduce sodium and water retention but increase the retention of potassium. In other words, these drugs stimulate the excretion of sodium and water in urine, while they block the excretion of potassium.
Sources: en.wikipedia.org
== Mass spectrometry == Generally this topic is discussed when covering tandem mass spectrometry fragmentation and occurs generally by the same mechanisms. For example, of a mechanism of alpha-cleavage, an electron is knocked off an atom (usually by electron collision) to form a radical cation. Electron removal generally happens in the following order: 1) lone pair electrons, 2) pi bond electrons, 3) sigma bond electrons. One of the lone pair electrons moves down to form a pi bond with an electron from an adjacent (alpha) bond. The other electron from the bond moves to an adjacent atom (not one adjacent to the lone pair atom) creating a radical. This creates a double bond adjacent to the lone pair atom (oxygen is a good example) and breaks/cleaves the bond from which the two electrons were removed.
==== Distribution ==== Following a 600 mg oral dose, peak plasma concentrations (Cmax) are achieved in approximately 2 hours under fasting conditions and 4 hours under non-fasting conditions. The presence of food alters absorption; the bioavailability of the tablet formulation decreases by 21–23% under moderate to high-fat conditions relative to fasting conditions. Ritonavir is highly bound (98–99%) to human serum proteins, primarily binding to serum albumin and α1-acid glycoprotein over a concentration range of 0.01 to 30 µg/mL. This extensive protein binding attenuates its free antiviral activity in vitro by approximately 20-fold. The drug exhibits a volume of distribution (Vd) of 0.41 ± 0.25 L/kg.
=== Pharmacodynamics === Enobosarm is a selective androgen receptor modulator (SARM), or a tissue-selective mixed agonist or partial agonist of the androgen receptor (AR). This receptor is the biological target of endogenous androgens like testosterone and dihydrotestosterone (DHT) and of synthetic anabolic steroids like nandrolone and oxandrolone. The affinity (Ki) of enobosarm for the AR is high and was measured as 3.8 nM in one study, or approximately 16.8% of that of DHT. Enobosarm shows enantioselectivity for the AR and has similar but somewhat lower potency than DHT in terms of activating the receptor. In addition to general activation of the AR, enobosarm induces the N/C interaction (the interaction of the amino terminus and carboxyl terminus) of the AR less potently than does DHT, but in any case promotes the N/C interaction concentration-dependently and to the same maximal extent as DHT. The AR is widely expressed in tissues throughout the body, including in the prostate gland, seminal vesicles, genitals, gonads, skin, hair follicles, muscle, bone, heart, adrenal cortex, liver, kidneys, and brain, among others. The effects of SARMs including enobosarm in many of these tissues have yet to be characterized.
Sources: en.wikipedia.org
LC/MS Preprocessing: SIRIUS can automatically detect and align chromatographic features across multiple samples, including adduct assignment. The preprocessing further provides quality metrics that enable users to prioritize and filter results for downstream analysis. Spectral Library (Analog) Search: SIRIUS enables rapid identity search and analog search against spectral libraries. An identity search matches the query spectrum against library spectra sharing the same precursor mass. Conversely, an analog search matches against library spectra with different precursor masses. These spectral library hits are auxiliary annotations alongside the CSI:FingerID results and do not influence the ranking of structure candidates. Substructure Annotations: Substructure annotations serve as a visualization tool to illustrate the connection between the input MS/MS spectrum, the predicted CSI:FingerID structure candidates, and any (analog) spectral library matches. This feature is based on the combinatorial fragmentation of the candidate structure and operates independently of the scoring algorithm CSI:FingerID uses to rank structure candidates. Structure Sketcher: The Structure Sketcher is a user interface component that enables manual modification of existing candidate structures or the creation of new ones. Users can integrate these manually-defined structures into the list of candidates for subsequent analysis.
==== European Union ==== In the European Union, meloxicam is licensed for other anti-inflammatory benefits including relief from both acute and chronic pain in dogs. Meloxicam is also licensed for use in horses, to relieve the pain associated with musculoskeletal disorders. 1998 (January): Meloxicam was authorised for use in cattle throughout the European Union, via a centralised marketing authorisation. 2006: The first generic meloxicam product was approved. 2024 (January): EMA issued an 'Opinion' on a change to this medicine's authorisation concerning the follow-up oral treatment after initial injectable administration in cats. This change remains as an 'Opinion', while the medication continues to be approved as usual.
Secretary of State for Transport Mark Harper announces that regulated train fares in Scotland will rise by 8.7% from April 2024. 22 December – A 78-year-old man has been charged in connection with the death of Marion Hodge of Lockerbie, who was last seen in 1984. 23 December – Multiple warnings for severe weather are issued for the north and west of Scotland following overnight snowfall. 24 December – Humza Yousaf delivers his first Christmas message as first minister, using the address to pay tribute to volunteers and frontline workers. A fleece from the world's first cloned mammal, Dolly the Sheep, is donated to National Museum Scotland. 26 December – A yellow weather warning is issued for heavy rain and high winds ahead of the arrival of Storm Gerrit, expected to cause disruption the following day. 27 December – Storm Gerrit brings widespread disruption to Scotland, with heavy rain, snow and high winds affecting much of the country. 28 December – Around 3,000 properties remain without power following Storm Gerrit. BMA Scotland, the Scottish branch of the British Medical Association, expresses its concerns about staffing levels in the NHS in Scotland, which it says is "dangerously low".
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.